Tianjin's biopharmaceutical companies have grown increasingly meticulous about tax compliance. Danabio embeds compliance controls across the entire R&D cycle, assigning each project a unique code and a separate auxiliary ledger so reimbursements, material requisitions and working hours all attach to a project number; specialized expenses such as clinical trial and registration fees only enter the books once contract, invoice and payment records match. Hezhi Pharmaceutical moved the compliance starting point to contract signing with a four-party joint review by business, legal, accounting and risk control teams, and built a digital compliance system connecting contracts, business ledgers, invoices and funds for automatic cross-checking. Jingye Fine Chemicals built its own data platform merging six systems, lifting filing data accuracy above 99 percent, while CanSino Biologics deployed RPA robots that verify invoice details around the clock and automatically return anomalies to the person who submitted them.
News Detail
Tianjin biopharma firms sharpen tax risk control with digital tools
China Tax News reports on how Tianjin biopharmaceutical companies use digital systems to control tax risk. Danabio embeds compliance into the whole R&D cycle, giving each project a unique code and separate auxiliary ledger so expenses, materials and hours all tie back to a project. Hezhi Pharmaceutical moved compliance to the contract stage with four-party joint review and built a digital system linking contracts, business ledgers, invoices and funds for automatic cross-checking. CanSino Biologics added RPA robots that verify invoice details around the clock and automatically reject anomalies.
2026-09-30